ArticleDrugs & aging2018
International Group for Reducing Inappropriate Medication Use & Polypharmacy (IGRIMUP): Position Statement and 10 Recommendations for Action.
Article in Drugs & aging, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 105 papers, 7 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
105 citing papers in PubMed, 7 syntheses or guidelines pooled it.
- Understanding the Cost Consequences of Pharmacist Roles in Managing Long-Term Illnesses: A Systematic Review.Saudi medical journal · 2026Pooled it
- Outcomes of deprescribing for people with life-limiting conditions: A systematic review.Palliative medicine · 2026Pooled it
- Cardiovascular risk associated with polypharmacy in heart failure: a systematic review and meta-analysis.ESC heart failure · 2026Pooled it
- Delegation of medication administration from registered nurses to non-registered support workers in community care settings: A systematic review with critical interpretive synthesis.International journal of nursing studies · 2022Pooled it
- Pooled it
- Deprescribing for Community-Dwelling Older Adults: a Systematic Review and Meta-analysis.Journal of general internal medicine · 2020Pooled it
- Systematic review and meta-analysis of second-generation antidepressants for the treatment of older adults with depression: questionable benefit and considerations for frailty.BMC geriatrics · 2019Pooled it
- Desprescribing antihypertensives in older people in primary care: subgroup analysis of the MINOR randomised clinical trial.International journal of clinical pharmacy · 2025Trial
- Effect of a patient-centred deprescribing procedure in older multimorbid patients in Swiss primary care - A cluster-randomised clinical trial.BMC geriatrics · 2020Trial
- The effect of providing prescribing recommendations on appropriate prescribing: A cluster-randomized controlled trial in older adults in a preoperative setting.British journal of clinical pharmacology · 2019Trial
- Potentially Inappropriate Prescription and Its Association with Index Hospitalization: A Multicenter, Cross-Sectional Study Using TIME Criteria.Drugs & aging · 2026Observational
- Review
- Optimizing Antifungal Use Through Interdisciplinary Intervention in the Hematology Unit.Journal of fungi (Basel, Switzerland) · 2026Article
- Patient Activation Among Individuals with Chronic Illness: A Cross-Sectional Study from Jordan.Healthcare (Basel, Switzerland) · 2026Article
- Effect of educational intervention on polypharmacy management among community pharmacists: An interrupted time series analysis.Annals of clinical epidemiology · 2026Article
- Editorial: Optimizing medication management in older adults: addressing polypharmacy, deprescribing and represcribing challenges.Frontiers in medicine · 2026Article
- Barriers and facilitators to deprescribing in primary care in Brazil: a qualitative study of pharmacists' perspectives mapped to the Theoretical Domains Framework.Geriatrics, gerontology and aging · 2026Article
- Association between socioeconomic status and dispensing of higher-risk drug classes and polypharmacy in older community-based populations: a nationwide cohort study.European journal of clinical pharmacology · 2025Article
- Long-term results of a multidisciplinary medication optimization program for older adults including primary care and hospital team.European journal of clinical pharmacology · 2025Observational
- A multidisciplinary meeting for generating a personalized pharmaceutical plan for older adults at hospital discharge: the IATROPREV study.British journal of clinical pharmacology · 2025Observational
45 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Globally, the number of drug prescriptions is increasing causing more adverse drug events, which is now a significant cause of mortality, morbidity, and disability that has reached epidemic proportions. The risk of adverse drug events is correlated to very old age, multiple co-morbidities, dementia, frailty, and limited life expectancy, with the major contributor being polypharmacy. Each characteristic alters the risk-benefit balance of medications, typically reducing anticipated benefits and amplifying risk. Current clinical guidelines are based on evidence proven in younger/healthier adult populations using a single disease model and their application to older adults with multimorbidity, in whom testing has not been conducted, yields a different risk-benefit prospect and makes inappropriate medication use and polypharmacy inevitable. Applying inappropriate clinical practice guidelines to older adults is antithetical to good healthcare, is likely to increase health inequity, and is associated with substantial negative clinical, economic, and social implications for health systems. The casualties are on the scale of a war or epidemic, yet are usually invisible in measures of healthcare quality and formal recommendations. Radical and rapid action is required to achieve a better quality of life for older populations and to remain true to the principles of medical professionalism and evidence-based medicine that place patients' interests and autonomy at the fore. This first International Group for Reducing Inappropriate Medication Use & Polypharmacy position statement briefly details the causes, consequences, and extent of inappropriate medication use and polypharmacy. This article outlines current strategies to reduce inappropriate medication use, provides evidence for their effect, and then proposes recommendations for moving forward with 10 recommendations for action and 12 recommendations for research. We conclude that an urgent integrated effort to reduce inappropriate medication use and polypharmacy should be a leading global target of the highest priority. The cornerstone of this position statement from the International Group for Reducing Inappropriate Medication Use & Polypharmacy is the understanding that without evidence of definite relevant benefit, when it comes to prescribing, for many older patients 'less is more'. This approach differs from most other current recommendations and guidance in medical care, as the focus is on what, when, and how to stop, rather than on when to start medications/interventions. Disrupting the framework that indiscriminately applies standard guidelines to older adults requires a new approach that better serves patients with multimorbidity. This transition requires a shift in medical education, research, and diagnostic frameworks, and re-examination of the measures used as quality indicators. In achieving this objective, we promote a return to some of the original concepts of evidence-based medicine: which considers scientific data (where it exists), clinical judgment, patient/family preference, and context. A shift is needed: from the current model that focuses on single conditions to one that simultaneously considers multiple conditions and patient priorities. This approach reframes the clinician's role as a professional providing care, rather than a disease technician.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.